Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s stock price fell 2.5% on Monday . The company traded as low as $4.79 and last traded at $4.75. 3,127 shares were traded during mid-day trading, a decline of 80% from the average session volume of 15,404 shares. The stock had previously closed at $4.87.
Wall Street Analysts Forecast Growth
Separately, Guggenheim cut their price target on shares of Nanobiotix from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, April 4th.
Read Our Latest Analysis on Nanobiotix
Nanobiotix Stock Performance
The business has a 50 day moving average of $4.25 and a 200-day moving average of $3.67.
Institutional Trading of Nanobiotix
Large investors have recently bought and sold shares of the business. Millennium Management LLC bought a new stake in Nanobiotix during the 4th quarter worth approximately $39,000. Jane Street Group LLC bought a new stake in Nanobiotix during the 4th quarter worth approximately $73,000. Geode Capital Management LLC bought a new stake in Nanobiotix during the 4th quarter worth approximately $29,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix during the 4th quarter worth approximately $139,000. 38.81% of the stock is owned by institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Stories
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
